GR20090100483A - Original synergetic anti-cancer effect of n-stearoyl and n-palmitoyl dopamines - Google Patents

Original synergetic anti-cancer effect of n-stearoyl and n-palmitoyl dopamines

Info

Publication number
GR20090100483A
GR20090100483A GR20090100483A GR20090100483A GR20090100483A GR 20090100483 A GR20090100483 A GR 20090100483A GR 20090100483 A GR20090100483 A GR 20090100483A GR 20090100483 A GR20090100483 A GR 20090100483A GR 20090100483 A GR20090100483 A GR 20090100483A
Authority
GR
Greece
Prior art keywords
stearoyl
palmitoyl
dopamines
cancer
medicines
Prior art date
Application number
GR20090100483A
Other languages
Greek (el)
Other versions
GR1007279B (en
Inventor
Αλεξανδρος Βαμβακιδης
Original Assignee
Αλεξανδρος Βαμβακιδης
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Αλεξανδρος Βαμβακιδης filed Critical Αλεξανδρος Βαμβακιδης
Priority to GR20090100483A priority Critical patent/GR1007279B/en
Publication of GR20090100483A publication Critical patent/GR20090100483A/en
Publication of GR1007279B publication Critical patent/GR1007279B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anti-cancer use (single or combination therapy with clinically used anti-cancer medicines) of N-stearoyl and N-palmitoyl dopamine for cancer cells of any kind. Use as synergetic medicines along with common anti-cancer medicines (paclitaxel, oxaliplatin, vincristine) causing severe neuropathetic pains. The n-stearoyl and n-palmitoyl dopamines increase the efficiency of the above mentioned anticancer medicines and act against the setting and range of the neuropathetic pain.
GR20090100483A 2009-09-08 2009-09-08 Original synergetic anti-cancer effect of n-stearoyl and n-palmitoyl dopamines GR1007279B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GR20090100483A GR1007279B (en) 2009-09-08 2009-09-08 Original synergetic anti-cancer effect of n-stearoyl and n-palmitoyl dopamines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20090100483A GR1007279B (en) 2009-09-08 2009-09-08 Original synergetic anti-cancer effect of n-stearoyl and n-palmitoyl dopamines

Publications (2)

Publication Number Publication Date
GR20090100483A true GR20090100483A (en) 2011-04-12
GR1007279B GR1007279B (en) 2011-05-25

Family

ID=43852597

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20090100483A GR1007279B (en) 2009-09-08 2009-09-08 Original synergetic anti-cancer effect of n-stearoyl and n-palmitoyl dopamines

Country Status (1)

Country Link
GR (1) GR1007279B (en)

Also Published As

Publication number Publication date
GR1007279B (en) 2011-05-25

Similar Documents

Publication Publication Date Title
PH12015501552A1 (en) Androgen receptor modulator and uses thereof
MX2015000821A (en) Compounds for targeted immunotherapy.
NZ595372A (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
JO3419B1 (en) Anticancer pyridopyrazines via the inhibition of fgfr kinases
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
WO2014145642A3 (en) Nrf2 small molecule inhibitors for cancer therapy
CR20120202A (en) METHODS AND COMPOSITIONS TO TREAT CANCER
MX366804B (en) R-spondin translocations and methods using the same.
AU2011338383A8 (en) Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
SG179161A1 (en) Tricyclic compounds and pharmaceutical uses thereof
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
TW201611831A (en) Novel antitumoral use of CABAZITAXEL
PH12014502032A1 (en) Treatment of brain cancer
MX365392B (en) Procaspase 3 activation by combination therapy.
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
MX2013002155A (en) Compounds for treatment of cancer.
WO2015040243A3 (en) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
EA201200190A1 (en) FULVESTRANT IN DOSE 500 MG FOR THE TREATMENT OF ADVANCED BREAST CANCER
AU2018244925A1 (en) Compositions for the treatment of drug-resistant tumors and methods of use thereof
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents
MX2010009697A (en) Improved anticancer treatments.
MX2011006532A (en) Anticancer compounds.
GR1007279B (en) Original synergetic anti-cancer effect of n-stearoyl and n-palmitoyl dopamines
RS20120482A1 (en) Diterpene compounds with antineoplastic activities and pharmaceutical compositions comprising same
NZ725303A (en) Anti-tumor agent containing taxane compound, and anti-tumor effect enhancer

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20110614